Abstract: The present invention relates to an improvement in a method for amplifying a target sequence of a target polynucleotide. The method comprises the step of forming extension products of an oligonucleotide primer at least along the target sequence or along an extended oligonucleotide primer. The extension products are copies of the target sequence. The improvement comprises forming the extension products in the presence of a second polynucleotide, to which the oligonucleotide primer hybridizes except for 1–10 nucleotides at the 3?-end of the oligonucleotide primer. Under the conditions chosen, the oligonucleotide primer is extended along the second polynucleotide in a controlled manner relative to extension of such primer along the target sequence, thus providing a positive control for the amplification reaction, which control may be qualitative or quantitative. Optionally, a modified oligonucleotide primer is included in the amplification reaction.

Abstract: The invention concerns novel polypeptides capable of interacting with the human topoisomerase III&agr; and the nucleic acid sequences coding for said polypeptides. The invention also concerns a method for identifying compounds capable of interacting with said polypeptides and a method for identifying molecules capable of modulating the interaction of the topoisomerase III&agr; with said polypeptides.

Abstract: Provided herein are novel peptide and nucleotide sequences, their pharmaceutical use, as well as novel polypeptides capable of inhibiting at least partially the interaction between presenilin 1 or presenilin 2 and the &bgr;-amyloid peptide precursor or a &bgr;-amyloid peptide; also provided are in vitro tests and methods for detecting molecules and in particular, molecules capable of inhibiting said interaction.

Abstract: Provided herein are novel polypeptides that are derived from human JNK3 proteins, variants of such polypeptides, their corresponding nucleotide sequences, and their uses.

Abstract: Enzyme combinations useful for destroying cells, particularly proliferative cells, are disclosed. In particular, a combination of the following enzymes has been found to enhance the toxicity of nucleoside analogues to proliferating cells: an enzyme that phosphorylates the non-toxic nucleoside analogue to generate a monophosphate analogue, an enzyme that phosphorylates the monophosphate analogue to generate a diphosphate analogue and an enzyme that phosphorylates the diphosphate analogue to generate a toxic triphosphate analogue. Vectors enabling the intracellular expression and transfer of the enzyme combinations, as well as their therapeutic use, particularly in anti-cancer gene therapy, are also disclosed.

Abstract: A transgenic rabbit which has in its genomic DNA sequences that encode apolipoprotein (a) and apolipoprotein B polypeptides which are capable of combining to produce lipoprotein (a), a process for creating such a rabbit, and the use of the rabbit to identify compounds which are effective in the treatment of human diseases which are associated with, induced and/or exacerbated by Lp(a) expression.

Abstract: This invention is directed to methods for stereospecifically preparing [(1-optionally substituted aryl)- or (1-optionally substituted heteroaryl)]-2-substituted ethyl-2-amines, having chirality at the 2-position, and to intermediates to the substituted ethyl-2-amines.

Abstract: This invention is directed to a process for preparing N6-substituted adenosine derivatives, to intermediates useful therefor and to methods of preparing these intermediates.